OMICSCOUTS GMBH

Their core work

OmicsScouts GmbH is a German biotech SME based in Freising, Bavaria, specializing in phosphoproteomics-based services for pharmaceutical drug discovery and biomarker identification. Their core offering — the DrugPhosphoProfiler platform — maps drug-induced changes in protein phosphorylation, giving researchers a mechanistic fingerprint of how compounds affect cellular signaling pathways. Beyond their own platform, they operate as a scientific partner in academic drug discovery consortia, contributing proteomics and target profiling expertise to projects focused on infectious diseases. They sit at the intersection of analytical proteomics and early-stage pharmaceutical R&D, serving both as a commercial service provider and a research collaborator.

What they specialise in

How they've shifted over time

OmicsScouts' H2020 activity begins with a service-innovation focus: their 2019 SME Instrument Phase 1 grant was about commercializing a phosphoproteomics platform for the broader drug discovery market, with no disease-area specialization evident. By 2020, their work had shifted toward a specific application domain — anti-infective drug discovery — contributing to an MSCA training network targeting the MEP pathway, a metabolic route found in bacteria and parasites but not in mammals. The trajectory points from platform builder toward disease-area specialist, with infectious diseases as their emerging scientific vertical.

OmicsScouts is deepening their focus on infectious disease drug discovery, making them most relevant for future consortia targeting antibacterial, antiparasitic, or antimalarial drug pipelines where phosphoproteomics can profile novel target engagement.

How they like to work

OmicsScouts has operated in two distinct modes: as a solo lead in an SME Instrument Phase 1 feasibility project, and as a specialist partner within a large MSCA Innovative Training Network spanning 10 partners across 7 countries. The contrast suggests they can both drive their own commercial innovation and integrate smoothly into academically-led consortia. As a small SME, their contribution is most likely a well-defined analytical service rather than consortium management or large-scale coordination.

OmicsScouts has worked with 10 unique partners across 7 countries through just two H2020 projects, a reasonable network breadth for an SME of their size. Their MepAnti participation likely connects them to academic institutions and pharmaceutical partners across multiple European member states.

What sets them apart

OmicsScouts occupies a narrow but defensible niche as an SME offering phosphoproteomics as a commercial analytical service specifically designed for early drug discovery — not a generic contract research lab, but a platform company with a defined methodology. Their location in Freising places them within the Munich life sciences corridor, close to TU Munich, Helmholtz centers, and major pharmaceutical operations. For consortium builders, they bring a rare combination of commercial service delivery and genuine scientific depth in target profiling that is uncommon at the SME scale.

Highlights from their portfolio

• DrugPhosphoProfiler
  As coordinator of this SME Instrument Phase 1 grant, OmicsScouts positioned themselves as the innovator behind a proprietary phosphoproteomics platform — this project defines their core commercial identity and differentiates them from generic proteomics providers.
• MepAnti
  Their largest project by far (EUR 252,788, 2020–2024), MepAnti places OmicsScouts inside a serious multi-country academic drug discovery consortium targeting the MEP pathway for novel anti-infective agents — a scientifically credible and medically relevant program.